modifies a nutritional intervention for stunting in Zimbabwean infants

Ethan K Gough,Thaddeus J Edens,Lynnea Carr,Ruairi C Robertson,Kuda Mutasa,Robert Ntozini,Bernard Chasekwa,Hyun Min Geum,Iman Baharmand,Sandeep K Gill,Batsirai Mutasa,Mduduzi N N Mbuya,Florence D Majo,Naume Tavengwa,Freddy Francis,Joice Tome,Ceri Evans,Margaret Kosek,Andrew J Prendergast,Amee R Manges,the Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial Team
DOI: https://doi.org/10.1101/2024.01.18.24301438
2024-03-04
Abstract:Child stunting is an indicator of chronic undernutrition and reduced human capital. Small-quantity lipid-based nutrient supplements (SQ-LNS) has been widely tested to reduce stunting, but has modest effects. The infant intestinal microbiome may contribute to stunting, and is partly shaped by mother and infant histo-blood group antigens (HBGA). We investigated whether mother-infant fucosyltransferase status, which governs HBGA, and the infant gut microbiome modified the impact of SQ-LNS on stunting at age 18 months among Zimbabwean infants in the SHINE Trial ( ). We found that mother-infant fucosyltransferase discordance and modified SQ-LNS efficacy. Infant age-related microbiome shifts in subspecies dominance from , a proficient human milk oligosaccharide utilizer, to or , proficient plant-polysaccharide utilizers, were partly influenced by discordance in mother-infant FUT2+/FUT3-phenotype, suggesting that a “younger” microbiome at initiation of SQ-LNS reduces its benefits on stunting in areas with a high prevalence of linear growth restriction.
Nutrition
What problem does this paper attempt to address?